Jeffrey E. Lancet

Moffitt Cancer Center — United States

Medicine · Health Sciences

61h-index15.1kcitations881works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(545), Myeloproliferative Neoplasms: Diagnosis and Treatment(193), Chronic Myeloid Leukemia Treatments(185), Chronic Lymphocytic Leukemia Research(120), Acute Lymphoblastic Leukemia research(92)

Publications880 total

Posttransplant MRD monitoring by <i>TP53</i> duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes
Blood Advances·2025Open Access
Supplementary Figure S4 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Figure S7 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Figure S6 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Figure S5 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Figure S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Table S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Figure S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
Blood Advances·2025Open Access
Supplementary Table S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis
Cardio-Oncology·2025· 1 citedOpen Access
Supplementary Data S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Table S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Data S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
Supplementary Figure S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
2025Open Access
The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes
Blood·2025Open Access
Outcomes of elderly (≥ 70) Acute Myeloid Leukemia (AML) patients receiving continued hypomethylating agent/venetoclax (HMA/VEN) versus allogeneic hematopoietic cell transplantation (HCT)
Blood·2025Open Access
Prospera (ABNL-MARRO 002): A randomized phase 2 study of pacritinib vs. hydroxyurea in patients with advanced proliferative chronic myelomonocytic leukemia (CMML)
Blood·2025Open Access
Early real-world experience with revumenib outside of a clinical trial setting: A single center retrospective review of efficacy and tolerability
Blood·2025Open Access
Treatment responses and survival of newly diagnosed older or unfit patients (pts) with IDH1/2-mutated Acute Myeloid Leukemia (AML): An analysis of the MARROW consortium
Blood·2025
page 1 of 44Next →

Frequent Co-authors

Rami S. Komrokji(19), Alan F. List(18), Richard M. Stone(10), Eric Padron(10), Hagop M. Kantarjian(10), Dale L. Bixby(9), Judith E. Karp(9), Stephen A. Strickland(8), David A. Sallman(8), Jörge E. Cortes(7), Amir T. Fathi(7), Farhad Ravandi(7), Kendra Sweet(7), Jonathan E. Kolitz(6), Matthew J. Wieduwilt(6), Jessica K. Altman(6), Daniel A. Pollyea(6), Paul J. Shami(6), Ivana Gojo(6), Guillermo Garcia‐Manero(6)